Clinical trial · Interventional
The Use of Lactobacillus Plantarum 299v in Treatment of Cancer Patients Who Received Home Enteral Nutrition
NCT03940768CI-TRIAL-00044343completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to assess the impact of Lactobacillus plantarum 299v on nutritional status, tolerance of enteral diet and the quality of life. Administration of this probiotic may potentially improve nutritional status and tolerance of enteral diet. It also may provide positive effect on quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lactobacillus plantarum 299v | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Lactobacillus plantarum 299v receivers
- description
- Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
- interventionNames
- Dietary Supplement: Lactobacillus plantarum 299v
- Dietary Supplement: Placebo
- type
- PLACEBO_COMPARATOR
- label
- Placebo receivers
- description
- Sanprobi IBS placebo 2 capsules per day for 4 weeks.
- interventionNames
- Dietary Supplement: Lactobacillus plantarum 299v
- Dietary Supplement: Placebo
Primary outcomes (7)
- measure
- Changes of fat mass
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age ≥18 yr., * the presence of cancer, artificial access to the alimentary tract (naso-gastric tube, gastrostomy, percutaneous endoscopic gastrostomy, jejunostomy, microjejunostomy), * qualification for home enteral nutrition, * written consent to take part in the study Exclusion Criteria: * age \<18 yr., * patients requiring home parenteral nutrition, * patients who are not being able to attend the visit in the study centre.
References
Publications (1)
- DERIVEDKazmierczak-Siedlecka K, Folwarski M, Skonieczna-Zydecka K, Ruszkowski J, Makarewicz W. The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition - study protocol for a randomized, double-blind, and placebo-controlled trial. Nutr J. 2020 Sep 11;19(1):98. doi: 10.1186/s12937-020-00598-w. PMID 32917221